What we’re doing.

Genevant Appoints Dr. Bo Rode Hansen as President & CEO and Dr. Mark Kay as an Independent Board Member

Key leadership appointments bolster Genevant’s team of world-class RNA experts and strengthen position as the leading company pursuing a multiple modality “pan-RNA” approach Development of in-house and partnered RNA programs on track, with the aim of delivering 5+ product candidates … Continued

BioNTech and Genevant Sciences Sign Strategic mRNA-Focused Partnership in Rare Diseases

Partnership combines Genevant’s industry-leading delivery technology and BioNTech’s cutting-edge mRNA drug discovery platform to develop best-in-class therapeutics BioNTech and Genevant will develop five products for rare diseases with high unmet medical need under the 50/50 co-development and co-commercialization collaboration Collaboration … Continued

Arbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA Therapeutics for Genetic Diseases

Genevant aims to advance 5-10 product candidates into the clinic by 2020 across RNAi, mRNA, and gene editing modalities using Arbutus’ LNP and ligand conjugate platforms Genevant will be led by Executive Chairman Paris Panayiotopoulos, former CEO of ARIAD Pharmaceuticals … Continued